Drug
Lanreotide
Lanreotide: highest development phase Post-Market, developed by Ipsen. 11 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lanreotide (Autogel formulation) NCT00149188 | Post-Market | Acromegaly |
| Lanreotide (Autogel formulation) NCT02683941 | Phase 3 | Neuroendocrine Tumors in Lung |
| lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval NCT00444873 | Phase 3 | Acromegaly |
| lanreotide (Autogel formulation) NCT00383708 | Phase 3 | Acromegaly |
| Lanreotide NCT00774930 | Phase 3 | Carcinoid Syndrome |
| lanreotide (Autogel formulation) NCT00353496 | Phase 3 | Endocrine Tumors |
| Lanreotide (Autogel formulation) NCT00234572 | Phase 2/3 | Acromegaly |
| lanreotide NCT00771888 | Phase 2/3 | Polycystic Liver Disease |
| lanreotide (Autogel formulation) NCT02365584 | Phase 2 | Intestinal Obstruction |
| lanreotide (Autogel formulation) NCT00326469 | Phase 2 | Neuroendocrine Tumours |
| Lanreotide NCT03012594 | Phase 2 | Gastrointestinal Motility Disorder |
Latest
No recent events.
Follow Lanreotide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.